Related references
Note: Only part of the references are listed.Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication
Morgan Murphrey et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients
Emma Guttman-Yassky et al.
ALLERGY (2022)
Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata
Alessio Gambardella et al.
DERMATITIS (2021)
Loss-of-function variants in C3ORF52 result in localized autosomal recessive hypotrichosis
Liron Malki et al.
GENETICS IN MEDICINE (2020)
JAK inhibitors for alopecia areata: a systematic review and meta-analysis
K. Phan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Dupilumab and alopecia: A Janus effect
Cataldo Patruno et al.
DERMATOLOGIC THERAPY (2019)
Follow-Up Study of the First Genome-Wide Association Scan in Alopecia Areata: IL13 and KIAA0350 as Susceptibility Loci Supported with Genome-Wide Significance
Dagny Jagielska et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Share Paper
